Summit Therapeutics
- Country
- 🇬🇧United Kingdom
- Ownership
- -
- Employees
- 105
- Market Cap
- $9.7B
- Introduction
Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.
AstraZeneca and Summit Therapeutics in Advanced Talks for $15 Billion Ivonescimab Licensing Deal
AstraZeneca is negotiating with Summit Therapeutics for a potential $15 billion licensing deal for ivonescimab, an experimental lung cancer drug that has shown promising results in late-stage trials.
Revolution Medicines and Summit Therapeutics Launch Clinical Collaboration to Test RAS Inhibitor Combinations with Bispecific Antibody
Revolution Medicines and Summit Therapeutics announced a clinical collaboration to evaluate three RAS(ON) inhibitors in combination with ivonescimab, a PD-1/VEGF bispecific antibody, across multiple solid tumor types.
TOLREMO Therapeutics Strengthens Leadership with Key Appointments as TT125-802 Shows Clinical Promise
TOLREMO therapeutics has appointed Alessandra Cesano, MD, PhD, to its Board of Directors and named Florian D. Vogl, MD, PhD, as Chief Medical Officer to strengthen leadership capabilities.
Bristol Myers Squibb Partners with BioNTech in $11.1 Billion Deal for Dual-Target Cancer Immunotherapy
Bristol Myers Squibb will pay BioNTech $1.5 billion upfront plus $2 billion in anniversary payments through 2028 for a 50% partnership in BNT327, a bispecific antibody targeting both PD-L1 and VEGF proteins.
Summit Therapeutics' Ivonescimab Shows Promising Results in Phase 3 NSCLC Trial
Summit Therapeutics reported statistically significant improvement in progression-free survival for ivonescimab plus chemotherapy versus BeiGene's Tevimbra combination in advanced squamous non-small cell lung cancer.
Akeso Secures FDA Approval for Novel Cancer Drug While Partner Summit Therapeutics Faces Sharp Stock Decline
Akeso has received FDA approval for its first internally developed cancer therapeutic, marking a significant milestone for the Chinese biopharmaceutical company's expansion into the US market.
Summit's Ivonescimab Shows Promise in Phase III Trial Against Established Lung Cancer Therapies
Summit Therapeutics and Akeso's bispecific antibody ivonescimab demonstrated superior progression-free survival compared to BeiGene's tislelizumab in squamous non-small cell lung cancer patients, adding to previous positive results against Merck's Keytruda.
Akeso Reports Positive Phase 3 Results for Ivonescimab in Lung Cancer, Building on Recent FDA Approval Success
Akeso announced positive Phase 3 results for ivonescimab, a novel PD-1/VEGF bispecific antibody, demonstrating superior tumor progression control when combined with chemotherapy compared to PD-1 inhibitor plus chemotherapy in lung cancer patients.
BioNTech's BNT327 Shows Promising 85% Response Rate in First-Line Treatment for Extensive-Stage SCLC
BNT327, a bispecific antibody targeting both PD-L1 and VEGF-A, demonstrated an 85.4% confirmed response rate when combined with chemotherapy in extensive-stage small cell lung cancer patients.
Summit Therapeutics Partners with Pfizer to Evaluate Novel Cancer Drug Combination Amid Financial Losses
Summit Therapeutics announces strategic collaboration with Pfizer to evaluate their cancer drug ivonescimab in combination with Pfizer's antibody drug conjugates for solid tumor treatment.